Biocerta Precision Diagnostics Expands DST Technology with Exclusive University of Miami Licensing Agreement and Strategic Partnership with Acumen Partners

Biocerta Precision Diagnostics has announced an exclusive licensing agreement with the University of Miami and a strategic development partnership with Acumen Partners. The agreements align Biocerta's scientific foundation and commercial execution to accelerate the availability of its CertaPath diagnostic platform, designed to guide oncologists toward effective and least toxic treatments for individual patients. Biocerta's platform directly addresses limitations in cancer care by using fresh tumor tissue to screen more than 200 FDA-approved compounds in 14 days, measuring cancer cell death and normal tissue toxicity. The agreements aim to accelerate the translation of the technology from the laboratory into clinical use.